15 completed. 15 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 1 | 6 | Completed 6 |
Follow cemiplimab: new trials by email Literature Review of cemiplimab trials Research Report on cemiplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) M1774, Cemiplimab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 61 | 2023-09-13 | 2026-09-14 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| Cemiplimab for Secondary Angiosarcomas Cemiplimab - Secondary Angiosarcoma, Locally Advanced Sarcoma | Phase 2 | Completed | Radboud University Medical Center | 18 | 2022-01-01 | 2024-10-31 |
| Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy Cemiplimab, ISA101b - Cervical Cancer | Phase 2 | Completed | Regeneron Pharmaceuticals | 113 | 2021-06-28 | 2025-09-08 |
| Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy Isatuximab, Cemiplimab - Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma | Phase 2 | Completed | Won Seog Kim | 37 | 2021-06-25 | 2026-04-27 |
| A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment BNT111, Cemiplimab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Completed | BioNTech SE | 184 | 2021-05-19 | 2026-01-08 |
| Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer Cemiplimab, Plerixafor - Metastatic Pancreatic Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2020-11-16 | 2024-02-23 |
| Cemiplimab in AlloSCT/SOT Recipients With CSCC Cemiplimab, Everolimus, Sirolimus - Cutaneous Squamous Cell Carcinoma, Advanced Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2020-11-03 | 2025-04-23 |
| Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Cemiplimab - Cutaneous Squamous Cell Carcinoma | Phase 2 | Completed | Regeneron Pharmaceuticals | 79 | 2020-03-10 | 2025-12-23 |
| A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab - Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | SillaJen, Inc. | 95 | 2018-06-19 | 2026-06-18 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Isatuximab SAR650984, Cemiplimab REGN2810 - Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Sanofi | 109 | 2018-02-21 | 2024-06-14 |
| PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy cemiplimab - Carcinoma, Basal Cell | Phase 2 | Completed | Regeneron Pharmaceuticals | 138 | 2017-06-29 | 2025-04-08 |
| Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma cemiplimab - Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Completed | Regeneron Pharmaceuticals | 432 | 2016-04-07 | 2025-05-28 |
| In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® Hiltonol - Melanoma, Head and Neck Cancer | Phase 2 | Completed | Oncovir, Inc. | 26 | 2015-03-01 | 2020-12-17 |
Melanoma (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Head and Neck Neoplasms (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Sarcoma (3) · Breast Neoplasms (2) · Colonic Neoplasms (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Basal Cell (1)
Regeneron Pharmaceuticals (4) · BioNTech SE (1) · Dana-Farber Cancer Institute (1) · EMD Serono Research & Development Institute, Inc. (1) · Oncovir, Inc. (1) · Palleon Pharmaceuticals, Inc. (1) · Radboud University Medical Center (1) · Sanofi (1) · Sensei Biotherapeutics, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · SillaJen, Inc. (1) · Won Seog Kim (1)
United States (13) · Italy (6) · Spain (6) · Australia (5) · Germany (5) · France (4) · South Korea (4) · Belgium (3) · Brazil (3) · Greece (3) · Canada (2) · Netherlands (2) · Austria (1) · Czechia (1) · Hungary (1)
David H Smith, MD (1) · Dung Le, MD (1) · Frederick P Smith, MD (1) · Glenn J Hanna, MD (1) · Kevin Staveley-O'Carroll, MD (1) · Nina Bhardwaj, MD, PhD (1) · Ron Weitzman, MD (1) · Wonseog Kim, MD, Ph.D (1)
PMID 29863979, PMID 29950349, PMID 31585957, PMID 31952975, PMID 32554615, PMID 33477979, PMID 33768419, PMID 34000246, PMID 34413166, PMID 36094839, PMID 36821617, PMID 37839734, PMID 37875144, PMID 38072158, PMID 38252908, PMID 38471711, PMID 39031963, PMID 39073799, PMID 39245360, PMID 40073374
2016 (2), 2017 (1), 2019 (1), 2023 (1), P01CA247886 (1), R44CA183075 (1)